A Phase 3 interventional study of Acetylsalicylic acid and Clopidogrel in Aortic Valve Stenosis, Cardiovascular Diseases and Heart Valve Diseases, sponsored by ECRI bv. Completed at 25 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-18.
Sponsored by ECRI bv · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 191 studies in Aortic Valve Stenosis with a site in Germany — 39 open to participants now, 58 under way, 3 of them phase 3. Aortic Valve Stenosis · Germany.
Among the 191 studies in Aortic Valve Stenosis with a site in Germany, this one is the 45th largest by enrollment of the 93 interventional ones that give a count, is one of 13 that started in 2016, is one of 6 in phase 3, and was the 79th registered.
1,026 studies on the registry are indexed under Aortic Valve Stenosis; 294 are open to participants now.
Browse Aortic Valve Stenosis studies →39 of the 191 studies in Aortic Valve Stenosis with a site in Germany are open now. Recruiting first, the newest first:
Erasmus Medical Center · Sites in Germany, Netherlands
Ages 70+
IHF GmbH - Institut für Herzinfarktforschung · Sites in Germany
Ages 18+
Idoven 1903 S.L. · Sites in Germany
Ages 18+ · Healthy volunteers
Institut für Pharmakologie und Präventive Medizin · Sites in Germany
Ages 18+
Ceric Sàrl · Sites in Germany, Austria, Estonia and 11 more countries
Ages 65–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 25 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
191 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 13 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 231 is above the median of 126 across 554 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 220 across the 93 interventional studies, 300 across the 98 observational. Of the 109 that completed or were terminated, 28 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 191 have an industry lead sponsor. The 10 most frequent:
ECRI bv is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
ECRI bv has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Aortic Valve Stenosis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07479992Idoven 1903 S.L.Multicenter Study for the Validation of Willem AI: Aortic StenoSis Early Diagnosis With AI-electrocardiogram Study | 2027-01 |
| NCT06493994University of LuebeckMyval TransAXillary Transcatheter Aortic Valve Replacement Multicenter Clinical Registry | 2027-01-30 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT07520591Cardiawave SAValvosoft Outcomes Registry for Real-World Evidence | 2027-06-30 |
| NCT05603520Heinrich-Heine University, DuesseldorfPhenotyping Heterogeneity and Regionality of the Aorta | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 191 studies in Aortic Valve Stenosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aortic valve is located between the left ventricle and the aorta. Patients with symptomatic, severe aortic valve stenosis conventionally have it surgically replaced requiring direct access to the heart through the chest. Transcatheter aortic valve replacement (TAVR) is now a well-established alternative for treating severe aortic valve stenosis. Both types of intervention improve prognosis and alleviate symptoms.
The optimal choice of blood thinning therapy after TAVR is unknown. It has been reported that leaflet thrombosis with reduced leaflet motion can occur and this phenomenon has been suggested to be potentially related with neurological events. In addition, the occurence of this phenomenon can be reduced with anticoagulation blood thinning therapy.
The purpose of this study is to evaluate if anticoagulation compared to the usual double platelet inhibitor therapy after TAVR can reduce the risk of leaflet thrombosis.
BACKGROUND: Transcatheter aortic valve replacement (TAVR) has become an established therapeutic option for patients with symptomatic, severe aortic valve stenosis, who are ineligible or at high risk for conventional surgical aortic valve replacement (SAVR). It was recently reported that leaflet thickening and reduced leaflet motion, verified by four-dimensional computed tomography (4DCT), was not uncommon after both TAVR and SAVR. It has been emphasized that this phenomenon should be further investigated for its effect on clinical outcomes (e.g. stroke) and valve durability. As this valve leaflet thickening and reduced motion could be reversed by oral anticoagulant (OAC) treatment and was not observed in patients on chronic OAC therapy, it has been hypothesized that this phenomenon could be related to possible leaflet thrombosis or a "thrombotic film" on the leaflets.
AIM: To evaluate whether a rivaroxaban-based strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing subclinical valve leaflet thickening and motion abnormalities - as detected by 4DCT-scan.
POPULATION: All patients undergoing successful TAVR by ileofemoral or subclavian access with an approved TAVR device will be screened for eligibility. Included subjects must provide written informed consent. Inclusion and exclusion criteria are listed below.
DESIGN: The GALILEO-4D trial will be conducted as a substudy of the multicenter, open-label, randomized, event-driven, active-controlled GALILEO trial. Patients will be 1:1 randomized to an antiplatelet-based strategy vs. rivaroxaban-based strategy - the randomization will adopt the same 1:1 randomization of the main GALILEO trial. In case the GALILEO-4D trial should still be continued after completion of the main GALILEO trial, this 1:1 randomization will be continued until inclusion of 150 patients in both treatment groups. In total, 300 patients will be randomized in the GALILEO-4D trial.
INTERVENTION: Subjects in the GALILEO-4D substudy will receive the same intervention as in the main GALILEO study. In addition, a 4DCT-scan and echocardiography will be performed at 90 days after randomization.
END POINTS: The primary endpoint constitutes the rate of patients with at least one prosthetic leaflet with > 50% motion reduction as assessed by cardiac 4DCT-scan (total N = 300). The secondary endpoints are listed below.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
Drug: Acetylsalicylic acid · Drug: Clopidogrel
Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
Drug: Acetylsalicylic acid · Drug: Rivaroxaban
Drug: Acetylsalicylic acid: 75 - 100 mg OD (for first 90 days only in arm 1)
Also known as: Asprin
Drug: Clopidogrel 75 mg OD for first 90 days
Also known as: Plavix
Drug: Rivaroxaban (Xarelto): 10 mg OD (once-daily)
Also known as: Xarelto
Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan
Reduced systolic leaflet excursion is classified as: (I) normal, (II) mildly reduced (\<50%), (III) moderate to severely reduced (\>50%), and (IV) immobile. Reduced systolic leaflet excursion is considered significant when it is \> 50% or immobile. Quantitative assessment of leaflet motion is performed with a blood pool inversion volume rendered cine reconstruction throughout the cardiac cycle evaluating the bioprosthetic leaflets.
Time frame: 3 months
The Rate of Prosthetic Leaflets With > 50% Motion Reduction as Assessed by Cardiac 4DCT-scan
The rate of prosthetic leaflets with RLM\> grade 3 as assessed by cardiac 4DCT
Time frame: 3 months
The Rate of Patients With at Least One Prosthetic Leaflet With Thickening as Assessed by Cardiac 4DCT-scan
The rate of patients with at least one prosthetic leaflet with hypoattenuated leaflet thickening (HALT) as assessed by cardiac 4DCT.
Time frame: 3 months
The Rate of Prosthetic Leaflets With Thickening as Assessed by Cardiac 4DCT-scan
The rate of prosthetic leaflet with HALT as assessed by cardiac 4DCT-scan
Time frame: 3 months
Aortic Transvalvular Mean Pressure Gradient (mmHg) as Determined by Transthoracic Echocardiography.
Transprosthetic mean pressure gradiënt as determined by transthoracic echocardiography at three months after randomization. scale \[0-100\]
Time frame: 3 months
Effective Orifice Area (cm^2) as Determined by Transthoracic Echocardiography.
Effective orifice area (cm2) as determined by transthoracic echocardiography at three months after randomization. scale \[0.1-4.0\]
Time frame: 3 months
Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT) - as Exploratory Analysis.
Death, Dichotomization by HALT
Time frame: 3 months
Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM)- as Exploratory Analysis.
Death, Dichotomization by RLM
Time frame: 3 months
Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT)- as Exploratory Analysis.
Thromboembolic event, Dichotomization by HALT
Time frame: 3 months
Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM) - as Exploratory Analysis.
Thromboembolic event, Dichotomization by RLM
Time frame: 3 months
| Milestone | ASA + Clopidogrel | Rivaroxaban + ASA |
|---|---|---|
| Started | 116 | 115 |
| Completed | 101 | 97 |
| Not completed | 15 | 18 |
| Withdrew: Death | 2 | 3 |
| Withdrew: Were not scanned | 8 | 13 |
| Withdrew: Scans could not be evaluated | 5 | 2 |
Reduced systolic leaflet excursion is classified as: (I) normal, (II) mildly reduced (\<50%), (III) moderate to severely reduced (\>50%), and (IV) immobile. Reduced systolic leaflet excursion is considered significant when it is \> 50% or immobile. Quantitative assessment of leaflet motion is performed with a blood pool inversion volume rendered cine reconstruction throughout the cardiac cycle evaluating the bioprosthetic leaflets.
| Participants | ASA + Clopidogrel | Rivaroxaban + ASA |
|---|---|---|
| Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan | 11 | 2 |
The rate of prosthetic leaflets with RLM\> grade 3 as assessed by cardiac 4DCT
| leaflets | ASA + Clopidogrel | Rivaroxaban + ASA |
|---|---|---|
| The Rate of Prosthetic Leaflets With > 50% Motion Reduction as Assessed by Cardiac 4DCT-scan | 14 | 3 |
The rate of patients with at least one prosthetic leaflet with hypoattenuated leaflet thickening (HALT) as assessed by cardiac 4DCT.
| Participants | ASA + Clopidogrel | Rivaroxaban + ASA |
|---|---|---|
| The Rate of Patients With at Least One Prosthetic Leaflet With Thickening as Assessed by Cardiac 4DCT-scan | 33 | 12 |
The rate of prosthetic leaflet with HALT as assessed by cardiac 4DCT-scan
| Leaflets | ASA + Clopidogrel | Rivaroxaban + ASA |
|---|---|---|
| The Rate of Prosthetic Leaflets With Thickening as Assessed by Cardiac 4DCT-scan | 53 | 16 |
Transprosthetic mean pressure gradiënt as determined by transthoracic echocardiography at three months after randomization. scale \[0-100\]
| mm Hg | ASA + Clopidogrel | Rivaroxaban + ASA |
|---|---|---|
| Aortic Transvalvular Mean Pressure Gradient (mmHg) as Determined by Transthoracic Echocardiography. | 10 ± 5 | 10 ± 5 |
Effective orifice area (cm2) as determined by transthoracic echocardiography at three months after randomization. scale \[0.1-4.0\]
| cm2 | ASA + Clopidogrel | Rivaroxaban + ASA |
|---|---|---|
| Effective Orifice Area (cm^2) as Determined by Transthoracic Echocardiography. | 1.8 ± 0.4 | 1.8 ± 0.5 |
Death, Dichotomization by HALT
| Participants | HALT (-) | HALT (+) |
|---|---|---|
| Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT) - as Exploratory Analysis. | 0 | 0 |
Death, Dichotomization by RLM
| Participants | RLM>2 (-) | RLM(+) |
|---|---|---|
| Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM)- as Exploratory Analysis. | 0 | 0 |
Thromboembolic event, Dichotomization by HALT
| Participants | HALT (-) | HALT (+) |
|---|---|---|
| Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT)- as Exploratory Analysis. | 2 | 0 |
Thromboembolic event, Dichotomization by RLM
| Participants | RLM>2 (-) | RLM(+) |
|---|---|---|
| Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM) - as Exploratory Analysis. | 2 | 0 |
Collected over 90 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ASA + Clopidogrel | 2/116 (1.7%) | 3/116 (2.6%) | 17/116 (14.7%) |
| Rivaroxaban + ASA | 3/115 (2.6%) | 7/115 (6.1%) | 16/115 (13.9%) |
| Event | ASA + Clopidogrel | Rivaroxaban + ASA |
|---|---|---|
| Major bleeding eventBlood and lymphatic system disorders | 1/116 | 4/115 |
| Thromboembolic eventCardiac disorders | 2/116 | 4/115 |
| Event | ASA + Clopidogrel | Rivaroxaban + ASA |
|---|---|---|
| minor bleedingBlood and lymphatic system disorders | 17/116 | 16/115 |
| Age, Continuous(years) | ASA + Clopidogrel | Rivaroxaban + ASA | Total |
|---|---|---|---|
| Mean | 80.5 ± 6.2 | 79.7 ± 7.3 | 80.1 ± 6.7 |
| Sex: Female, Male(Participants) | ASA + Clopidogrel | Rivaroxaban + ASA | Total |
|---|---|---|---|
| Female | 42 | 41 | 83 |
| Male | 74 | 74 | 148 |
| Race and Ethnicity Not Collected(Participants) | ASA + Clopidogrel | Rivaroxaban + ASA | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Body-mass index(kg/m^2) | ASA + Clopidogrel | Rivaroxaban + ASA | Total |
|---|---|---|---|
| Mean | 27.8 ± 5.1 | 27.7 ± 6.5 | 27.8 ± 5.8 |
| Hypertension(Participants) | ASA + Clopidogrel | Rivaroxaban + ASA | Total |
|---|---|---|---|
| Count of participants | 95 | 98 | 193 |
| Diabetes Mellitus(Participants) | ASA + Clopidogrel | Rivaroxaban + ASA | Total |
|---|---|---|---|
| Count of participants | 27 | 21 | 48 |
| STS risk score(%) | ASA + Clopidogrel | Rivaroxaban + ASA | Total |
|---|---|---|---|
| Mean | 3.0 ± 2.1 | 2.8 ± 1.5 | 2.9 ± 1.8 |
| STS risk category - High(Participants) | ASA + Clopidogrel | Rivaroxaban + ASA | Total |
|---|---|---|---|
| Count of participants | 3 | 1 | 4 |
20 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of May 2016, a primary completion of Dec 2018 and a completion of Mar 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2020, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban
ECRI bv